Published On: Wed, Oct 19th, 2016

MacroGenics, Inc. (NASDAQ:MGNX) Latest Broker Views


A number of investment brokers have recently updated their price targets on shares of MacroGenics, Inc. (NASDAQ:MGNX).

Most recent broker ratings

09/07/2016 – Cowen began new coverage on MacroGenics, Inc. giving the company a “outperform” rating.

08/04/2016 – MacroGenics, Inc. was downgraded to “neutral” by analysts at Citigroup.

05/18/2016 – MacroGenics, Inc. had its “outperform” rating reiterated by analysts at Leerink Swann. They now have a USD 47 price target on the stock.

04/07/2016 – BTIG Research began new coverage on MacroGenics, Inc. giving the company a “buy” rating. They now have a USD 35 price target on the stock.

02/25/2016 – MacroGenics, Inc. had its “equal-weight” rating reiterated by analysts at Morgan Stanley. They now have a USD 20 price target on the stock.

02/18/2016 – Janney Montgomery Scott began new coverage on MacroGenics, Inc. giving the company a “buy” rating. They now have a USD 36 price target on the stock.

10/05/2015 – MacroGenics, Inc. had its “outperform” rating reiterated by analysts at Oppenheimer. They now have a USD 48 price target on the stock.

08/06/2015 – MacroGenics, Inc. had its “buy” rating reiterated by analysts at Stifel Nicolaus. They now have a USD 56 price target on the stock.

07/08/2015 – MacroGenics, Inc. had its “buy” rating reiterated by analysts at Roth Capital.

03/04/2015 – MacroGenics, Inc. had its “buy” rating reiterated by analysts at Bank of America Merrill Lynch. They now have a USD 43 price target on the stock.

09/30/2014 – MacroGenics, Inc. had its “outperform” rating reiterated by analysts at Wedbush. They now have a USD 52 price target on the stock.

11/04/2013 – Lazard Capital Markets began new coverage on MacroGenics, Inc. giving the company a “buy” rating.

The share price of MacroGenics, Inc. (NASDAQ:MGNX) was up +1.27% during the last day of trading, with a day high of 26.34. 174967 shares were traded during the last session.

The stock’s 50 day moving average is 29.58 and its 200 day moving average is 26.37. The stock’s market capitalization is 889.16M. MacroGenics, Inc. has a 52-week low of 14.84 and a 52-week high of 36.11.

MacroGenics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company operates through developing monoclonal antibody-based therapeutics for cancer, autoimmune and infectious diseases segment. It develops therapeutic product candidates using its antibody-based technology platforms and in partnership with other biopharmaceutical companies. It has a pipeline of product candidates in human clinical testing, primarily against various cancers. Its product candidates include margetuximab, enoblituzumab, MGD006, MGD007, MGD011, MGD009, MGD013, MGD010, teplizumab and MGD014. Its clinical product candidate, margetuximab, is a monoclonal antibody directed against human epidermal growth factor receptor 2, (HER2), including certain types of breast and gastroesophageal cancers.